Product category:
Contract research
News Release from: Chiltern International
Edited by the Laboratorytalk Editorial
Team on 15 October 2003
Steady growth in Spain
Ever increasing demand is reported on fifth birthday of clinical research organisation's Spanish operation
Clinical research organisation Chiltern International is celebrating the fifth birthday of its Spanish office The company's Spanish team - based at Tres Cantos, Madrid - has enjoyed steady and consistent growth over the past half decade - not only reflecting the importance of clinical research, but also the role of European countries in clinical trials
This article was originally published on Laboratorytalk on 10 Feb 2004 at 8.00am (UK)
Related stories
General manager for Chiltern France
Claude Albrecht will be responsible for ensuring high levels of service to clients, focussing on the development of the French operation
Long term strategy the key to success
In a recent lecture to biomedical students at Kings College London, Faiz Kermani outlined how more and more R and D projects have been given the green light over the last six months
In the past five years, staff levels have grown from less than ten to more than 50 and there has been a 30% year-on-year expansion in the number of projects being undertaken.
These projects include studies involving infectious disease, transplantation, cardiovascular, oncology, the central nervous system, ophthalmology and respiratory disorders.
And in order to satisfy the strong continuing demand for clinical research services in southern Europe, Chiltern Spain's operations now directly cover Portugal and Italy through the use of national-based staff.
"The past five years have been tremendously exciting and we are very proud to have worked with a number of pharmaceutical and biotech companies on more than 100 clinical trials developing new medicines," commented Lewis Cameron, general manager of Chiltern Spain.
"Another important aspect of our work has been collaboration with investigators to develop new clinical strategies that will improve the quality of life for patients.
"Spain can offer drug companies several advantages when it comes to clinical development," added Mr Cameron.
"With the right partner and a pro-active clinical team, studies can be set-up on time with access to an important pool of clinical trial patients and investigators only too happy to be involved in clinical research".
Recently, Chiltern Spain successfully completed the pan-European Gracia study (Grupo de Anlisis de la Cardiopata Isqu?mica Aguda, or Acute Ischaemic Heart Disease Group Study) having been involved in the operational running of the study at recruitment stage then monitoring the trial to ensure that it was carried out to the required international standards.
• Chiltern International: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
